The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial.
Asger R BihletInger ByrjalsenJeppe R AndersenAlan ReynoldsNicholas LarkinsPeter AlexandersenHelene RovsingRobert MootsPhilip G ConaghanPublished in: Osteoarthritis and cartilage (2024)
Treatment with APPA 800 mg twice daily for 28 days in subjects with symptomatic knee OA was not associated with significant symptom improvement compared to placebo. The treatment was well-tolerated and safe. While the study was not powered for such analysis, pre-planned subgroup analyses showed a significant effect of APPA in subjects with nociplastic pain/severe OA, indicating that further research in the effects of APPA in appropriate patients is warranted.
Keyphrases
- double blind
- placebo controlled
- knee osteoarthritis
- phase iii
- clinical trial
- total knee arthroplasty
- end stage renal disease
- open label
- phase ii
- ejection fraction
- newly diagnosed
- chronic pain
- study protocol
- chronic kidney disease
- physical activity
- peritoneal dialysis
- prognostic factors
- pain management
- radiation therapy
- patient reported outcomes
- spinal cord injury
- replacement therapy